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ARTICLE
Inferring structural variant cancer cell fraction
Marek Cmero 1,2,3,4,5,78*, Ke Yuan 6,7,78, Cheng Soon Ong 8,9,10, Jan Schröder4, PCAWG Evolution and
Heterogeneity Working Group, Niall M. Corcoran1,2, Tony Papenfuss 4, Christopher M. Hovens1,2,
Florian Markowetz 7, Geoff Macintyre 3,7* & PCAWG Consortium
We present SVclone, a computational method for inferring the cancer cell fraction of
structural variant (SV) breakpoints from whole-genome sequencing data. SVclone accurately
determines the variant allele frequencies of both SV breakends, then simultaneously esti-
mates the cancer cell fraction and SV copy number. We assess performance using in silico
mixtures of real samples, at known proportions, created from two clonal metastases from the
same patient. We find that SVclone’s performance is comparable to single-nucleotide var-
iant-based methods, despite having an order of magnitude fewer data points. As part of the
Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium, which aggregated whole-
genome sequencing data from 2658 cancers across 38 tumour types, we use SVclone to
reveal a subset of liver, ovarian and pancreatic cancers with subclonally enriched copy-
number neutral rearrangements that show decreased overall survival. SVclone enables
improved characterisation of SV intra-tumour heterogeneity.
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The clonal theory of cancer evolution
1 posits that cancers
arise from a single progenitor cell that has acquired
mutations conferring selective advantage, resulting in the
expansion of a genetically identical cell population or clone. As a
cancer grows, a process akin to Darwinian species evolution
emerges with subsequent genetically distinct populations arising
from the founding clone via the continual acquisition of advan-
tageous genomic aberrations. Consequently, tumours are likely to
consist of a genetically heterogeneous combination of multiple
cell populations, the extent of which has been revealed through
the use of whole-genome sequencing2,3. As clones can respond
differently to therapy4, understanding this cellular diversity has
important clinical implications5.
The mutations belonging to each clone in a tumour can be
interrogated using bulk whole-genome sequencing, with mutation
detection subject to factors such as sequencing depth and quality,
tumour cellularity and mutation copy number6. The expansion of
each clone over the life of a tumour is encoded in the allele fre-
quency of somatic mutations7. To characterise the clonal composi-
tion of a tumour, the variant allele frequency (VAF) must be
converted to a cancer cell fraction (CCF), the fraction of cancer cells
within which the variant is present. Events appearing in all cancer
cells (CCF= 100%) are considered clonal and due to a pervasive
expansion. Events appearing in a subset of cells (CCF < 100%) are
considered subclonal and part of an ongoing expansion. Estimating
the cancer cell fraction of events is challenging, as the observed
variant allele frequency depends on the amount of normal cell
admixture (purity) and local copy number.
Given these challenges, previous computational approaches for
estimating CCF have focused on individual facets of this com-
plexity, commonly limiting their view to single-nucleotide variants
(SNVs)8–13 or somatic copy-number aberrations (SCNAs)14–16.
This has left the clonality of balanced rearrangements largely
unexplored, despite their implication in oncogenic fusions17 and
subclonal translocations conferring drug-resistant phenotypes18.
While SNV-based approaches have provided solutions to the
problem of downstream inference of mutation CCF, they cannot
be used for structural variant (SV) breakpoint data as: (i) no
complete and robust methodology exists yet to calculate VAFs
from SVs (Fan et al.19 provides a limited framework that does not
correct for DNA-gains or support all SV types), (ii) SVs them-
selves can cause copy-number changes (background copy num-
bers must therefore be inferred differently), (iii) SVs are composed
of two ends, each with a potentially different VAF, and (iv) due to
the relatively small number of data points (on average compared
with SNVs), false-positive SVs greatly diminish clustering per-
formance, hence a robust filtering methodology is required to
consider only high-confidence SVs.
To address this gap, we present SVclone, an algorithmic
approach that infers CCFs of SV breakpoints. It considers all types
of large-scale structural variation (SV), including copy-number
aberrant and copy-number neutral variation. The Pan-Cancer
Analysis of Whole Genomes (PCAWG) Consortium has aggregated
whole-genome sequencing data from 2658 cancers across 38
tumour types generated by the ICGC and TCGA projects. These
sequencing data were re-analysed with standardised, high-accuracy
pipelines to align to the human genome (reference build hs37d5)
and identify germline variants and somatically acquired mutations,
as described in20. Here we apply SVclone to these large-scale data to
generate insight into patterns of clonality of structural variation
across a large number of cancer types, and identify functionally
important and clinically relevant observations.
Results
Algorithm overview. The SVclone algorithm consists of five
steps: annotate, count, filter, cluster and post-assign. A graphical
representation of the SVclone pipeline can be found in Fig. 1a.
Here we briefly summarise each step with detailed explanations
appearing in the Methods section.
Annotate: SV calls are required as input into the annotate step
(single-nucleotide resolution paired SV loci), and the correspond-
ing whole-genome sequencing file in BAM format. The annotate
step determines the read directionality of SVs and classifies the
SV type.
Count: The count step estimates the supporting and normal
(non-supporting) read counts and computes SV VAFs.
Filter: The filter step removes low-quality SVs and those with
missing information, and, given copy-number calls, infers the
background copy number for each break-end.
Cluster: The cluster step simultaneously estimates the mutated
copy number of SVs, the number of clusters and their respective
CCF means. Allele frequencies from both break-ends of each SV
are used to perform inference.
Post assign: The post-assign step (re)assigns variants a most-
likely mutated copy number and CCF, given the previously
obtained clustering configuration.
Estimation of SV allele frequency. SV variant allele frequencies
can be estimated in the same way as SNVs: the number of variant
reads divided by the total number of reads observed at the SV
breakpoint. The challenge for SVs is that many reads are split
across the breakpoint making extracting accurate estimates for
these read counts difficult. To explore how best to deal with this
challenge we simulated reads from SVs with known allele fre-
quency, at varying tumour purity. We then implemented an
optimised approach for computing a VAF from these read counts
(see Methods). The simulations revealed that the VAF estimates
were accurate, independent of purity, except for duplications
(Fig. 1c). Duplications showed an increased normal read count
due to DNA gains showing no loss of normal DNA (Fig. 1b). To
account for this bias, we introduced a scaling factor that incor-
porates tumour purity to calibrate the supporting read counts.
This corrected for the bias and showed accurate estimation of the
underlying VAF (Fig. 1c).
In silico subclonal mixing of tumours for validation. Recently,
a number of efforts have been made to simulate datasets with
known subclonal structure to assess the performance of algo-
rithms that infer the CCF of mutations21,22. However, these have
been limited to simulating SNVs and copy-number changes. To
date, a gold standard dataset to test the performance SV cancer
cell fraction inference does not exist. Therefore, we created a
dataset of tumour samples with known SV subclonal structure.
Rather than simulate SVs, we opted to mix two whole-genome
sequenced samples from the same patient23, in silico, at known
subclonal proportions (Fig. 2a). By mixing tumour sequence data,
we maintained many of the noise characteristics of real sequence
data. Our samples consisted of a set of three-cluster mixtures with
SV and SNVs subsampled with known clonal frequencies at 10%
increments, as well as four and five-cluster mixtures created by
subsampling odd and even chromosomes at different frequencies
(Fig. 2a). The prostate cancer samples used to create the mixtures
had no evidence of subclonality (Supplementary Fig. 2d from
Hong et al.23), and had similar read coverage and tumour purity.
Optimal cancer cell fraction versus ground truth. Our in silico
mixtures allowed us to explore some of the fundamental noise
properties of CCF distributions. As the read counts supporting
the SVs and SNVs in our mixed samples were subject to noise
(approximately binomially distributed), we hypothesised that the
resulting CCF estimates must also be noisy (approximately
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normally distributed). To observe this, we estimated an ‘optimal’
CCF for each variant, which was calculated using the VAF and
inferring multiplicity from the true mixture proportion (see
Methods). This estimate allowed us to observe the optimal CCF
distributions (Fig. 2c). Indeed, we observed that subclonal
populations were approximately normally distributed, and those
with similar CCFs had overlapping distributions (Fig. 2b).
These optimal CCF estimates also allowed us to explore any
differences between SV and SNV CCF estimation. Overall, 234
high-confidence SVs and 9810 SNVs were called across both
metastasis samples. The lower number of SVs resulted in the
optimal CCF estimates having less clear CCF peaks than SNVs
(Fig. 2b). These data highlight the difficulty in estimating CCFs
for SVs as compared with SNVs. In addition, at the variant level,
CCFs of SVs had a slightly higher mean error (ME) compared
with SNVs (0.0461 vs. 0.015 across all cluster mixtures; per
mixture results are shown in Fig. 2c).
Given the ground truth, these data also allowed us to determine
the optimal per-variant cutoff for determining whether a variant
was subclonal (Fig. 2d). We found that taking the max or mean
CCF of both SV ends resulted in the highest AUC (~0.90), which
was also approximately equal to the AUC obtained by classifying
SNVs. The optimal CCF cutoffs for determining subclonality
were 0.69 and 0.72 for SVs (using mean CCF) and SNVs
respectively—to simplify this, we used a cutoff of 0.7 for both
variant types for all downstream analyses.
Performance assessment. SVclone is chiefly designed to deter-
mine the CCF of SVs in a single, whole-genome sequenced
tumour sample. Common downstream analyses of these data
include analysing the number of subclonal populations in a
sample24 and observing which SVs are clonal or subclonal25. As
such, we designed performance metrics to interrogate such vari-
ables including: cluster number error, mean cluster CCF error,
mean variant CCF error, and sensitivity and specificity for calling
a variant subclonal. As one of the key features of any CCF
inference algorithm is to estimate the number of chromosome
copies of a variant (known as multiplicity), we also observed the
mean multiplicity error.
To our knowledge, no other method for estimating SV CCF
exists for direct comparison. Instead we opted to compare to two
representative, state of the art methods for estimating the CCF of
SNVs, PyClone10, and copy number, Battenberg15, from single
samples. In addition, we also ran SVclone in SNV clustering
mode, which uses Ccube’s clustering model26. Performance is
summarised in Fig. 3, and a breakdown of the performance under
each measure can be found below.
Cluster number error: This metric indicates how effective the
given clustering algorithms were at inferring the correct number
of clusters. SVclone applied to the in silico mixtures was able to
identify the correct number of clusters in 7 of 11 cases (Fig. 3).
SVclone’s SNV clustering found the correct number of clusters in
5/11 cases, compared with PyClone’s 4/11, suggesting that SVs
may have a slight advantage in identifying the correct number of
underlying clusters.
Mean cluster CCF error: Mean cluster CCF error was generally
higher in the SV data, with an average mean error of 0.0913,
compared with 0.0412 and 0.0756 observed in the SNV data by
SVclone and PyClone respectively. This is likely due to the variant
number differences, as the comparatively larger number of SNVs
is likely to lead to more accurate cluster CCF estimates.
Mean variant CCF error: Similarly, mean variant CCF error
was slightly higher in the SV data than other methods. SV CCFs
had an average mean error of 0.0873, compared with −0.034 for
SVclone SNVs, −0.0213 for PyClone, and 0.0375 for Battenberg.
Slightly higher error rates for SV CCFs are expected, given that
the optimal (i.e. best obtainable given knowledge of cluster
means) CCF mean errors averaged 0.0408 and 0.002 for SVs and
SNVs respectively (Fig. 2c). Notably, while Battenberg performed
on average better than SVclone in terms of mean variant CCF
error for the three-cluster mixes, SVclone performed better on the
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four- and five-cluster mixtures, demonstrating SVclone’s advan-
tage in being able to consider >2 subclones. SVclone’s SNV
clustering and PyClone displayed similar mean error trends
across the mixtures. Given the relatively smaller number of
variants used in the clustering compared with SNVs, and the
fewer data points used to infer fraction compared with SCNAs,
SV CCF mean errors were in general comparable to other
methodologies, with <0.05 absolute difference, on average, across
the mixtures.
Sensitivity and specificity for calling a variant subclonal:
SVclone’s SV estimates demonstrated similar sensitivity to SNVs
when classifying a variant as subclonal, with an average sensitivity
of 0.670 (compared with an SNV sensitivity of 0.6643). The SVs
had a lower specificity (0.8852 vs. 0.952 with SNVs). PyClone
displayed a lower sensitivity, but higher specificity than the other
methods at 0.577 and 0.9687 respectively. Battenberg had the
highest average sensitivity and specificity (sens= 0.747, spec=
0.9175), which is expected given the number of data points
(germline SNVs) used by Battenberg to infer each copy-number
fraction.
Multiplicity error: Multiplicity error represents the difference
in the multiplicity inferred from clustering, compared with the
inferred multiplicity given the ‘true’ CCF cluster mean (as
multiplicity cannot directly be observed). As PyClone averages
across all possible multiplicities, and does not directly estimate
multiplicity, we did not consider PyClone for this metric. Average
multiplicity errors were −0.0391 for SVs and 0.1029 for SNVs.
The lower multiplicity error rate in SVs is likely due to the
subclonal copy-number inference model (only SNVs with clonal
copy numbers were considered), which allows for non-integer
copy numbers. The mean multiplicity error for clonal SVs across
the three-cluster mixtures was −0.1239, similar in absolute terms
to the SNV multiplicity error (0.1029).
SVclone’s comparable performance to SNV-based clustering
indicates that clonal structure can be effectively reconstructed
with high concordance and accuracy, despite the relative deficit in
variant number. This means that the clonal structure of a tumour
can be inferred from SNVs and SVs independently and their
results compared. However, if it is assumed that the clonal
populations in a sample share the same SNVs and SVs, we have
also provided an option to cluster both SVs and SNVs using the
same clustering framework. This is particularly powerful when
considering model-based post-assignment. SNV CCF posterior
can be integrated with SV read counts’ likelihood to make
assignment calls and vice versa (see Supplementary Fig. 1). By
combining these data types overall performance can be increased.
Two of SVclone’s unique design features also warranted further
performance assessment: (1) SVclone incorporates background
SCNA states from both breakpoint ends into its clustering model;
and (2) SVclone clusters variants in clonal and subclonal copy-
number regions. Here, we sought to quantify the advantages of
both approaches over ‘naive’ approaches which considered only
one breakpoint for each SV, or used only variants in clonal copy-
number regions.
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To compare the performance of SVclone’s dual-end clustering
model, to a single end, we ran the respective SV sides from the
three-cluster in silico mixtures through SVclone’s single-end
(SNV) model, and compared the clustering performance to the
dual-end model. Performance is summarised in Fig. 4. Figure 4
shows that dual-end model outperforms the single-end model
across mean variant CCF error, mean multiplicity error, and
mean cluster CCF error across almost all mixes. Only the cluster
number of the 50–50 mix was incorrectly inferred, compared with
the single-end model which was correct, However, we would
expect only two clusters given the 50–50 mixture split and thus
the dual-end model’s result is likely more parsimonious with the
data. Interestingly, the single-end model showed a higher
subclonal classification sensitivity, but a lower specificity than
the dual-end model. Given that this metric represents a sensitivity
and specificity trade-off, we generated a ROC curve (Supplemen-
tary Fig. 2). Considering the AUC indicates that the dual-end
model is preferable (AUC of 0.8234 vs. 0.8095 for the dual and
single-end models respectively).
We further hypothesised that the dual-end model was more
robust to SCNA noise. To investigate this point, we selected the
70–30 in silico mixture due to its low variant CCF error, and
perturbed copy number in the following ways: (i) major allele copy
number− 1 (CN− 1 for short), (ii) major allele copy number+ 1
(CN+ 1), and (iii) subclonal copy-number fraction +/−0.3, where,
0.3 is added to the copy-number fraction if the resulting fraction is
<0.9, otherwise we subtract 0.3 (see Methods for further details).
We performed these experiments for the dual-end model,
perturbing one side and both sides in separate runs. As expected,
we found that the CN-perturbed runs showed slightly worse
performance across the measured metrics compared with the
unperturbed runs (Supplementary Fig. 3). In general, variant-level
metrics were more severely affected than cluster-level metrics. All
perturbations performed similarly, with CN− 1 (experiment i) on
both sides being the most affected scenario. Mean variant CCF was
most significantly affected with a 0.27 error in the CN− 1 scenario
on both sides (compared with 0.07 in the unperturbed model).
Mean cluster CCF error was only mildly affected, but was also most
significant for the CN− 1 on both sides scenario (0.16 vs. 0.11 ME
in the unperturbed data). The CN− 1 experiments were the only
ones that caused an error in the cluster number. Supplementary
Fig. 4 shows the effects of the perturbation experiments on the
single-end model versus the dual-end model (where only one side is
perturbed). The dual-end model was more robust to perturbation
across all metrics for all perturbations except for cluster number
with the CN− 1 experiment (where one extra cluster was called),
subclonal classification sensitivity in the CN− 1 experiment and a
slightly worse mean multiplicity error in the CN+ 1 scenario.
Interestingly, mean cluster CCF error was still lower in the over-
clustered case. Importantly, the mean variant CCF error and mean
cluster CCF error were lower in all cases when considering the
perturbed dual-end model versus the perturbed single-end. In
summary, these data show that the dual-end model is more robust
to copy-number noise than the single end. Copy-number addition
errors were better tolerated than subtraction errors, and a mis-
estimation of copy-number fraction resulted in errors somewhere
between the two. However, mean cluster CCF error and cluster
number were minimally affected, suggesting that poor CN
estimation effects are largely restricted to errors in variant-level
estimates.
Finally, we compared SVclone’s performance using SVs in both
clonal and subclonal copy-number regions, to clonal only.
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Performance is summarised in Fig. 5. Utilising all available SVs
improved the performance significantly across all metrics (apart
from subclonal classification specificity) compared with clustering
SVs with clonal background copy numbers states only.
Clonality analysis of 1705 whole-genome sequenced tumours.
We applied SVclone to 1705 WGS samples from the pan-cancer
analysis of whole genomes (PCAWG) project (dcc.icgc.org/
pcawg)20,27, clustering both SVs and SNVs separately. An analysis
of the clonality of putative driver SV events can be found in
Dentro, et al.30 Here, we sought to observe any differences in the
clonal structure of SVs compared with SNVs. Downstream ana-
lysis was performed on 23 tumour types showing ≥20 samples,
with >10 SVs, and >10 SNVs, and sufficient power to detect
subclonality (total n = 1169, see Methods).
A comparison of the fraction of subclonal SVs versus SNVs
showed different patterns across tumour types (Fig. 6a). Tumour
types showing a greater proportion of subclonal SVs versus SNVs
included 100% of lung squamous cell carcinomas, and 92% of
both colorectal adenomas and ovarian adenocarcinomas. In
contrast, 23% of biliary adenocarcinomas had a greater propor-
tion of subclonal SNVs versus SVs (Supplementary Table 1).
Some cancers also contained subsets of samples with distinct
patterns of clonality, for instance, liver cancers contained a cluster
of 19 samples with high SV subclonality (≥50%) and low SNV
subclonality (<30%).
One unique feature of SVclone is that it determines the
clonality of copy-number neutral rearrangements (inversions and
inter-chromosomal translocations). We applied a test for
enrichment of subclonal copy-number neutral rearrangements
across the PCAWG cohort. A total of 177 samples across 28
cancer types exhibited a subclonal copy-number neutral rearran-
gement (SCNR) pattern (e.g. Fig. 6c–f, see Supplementary Fig. 5
for the distribution of the pattern across histologies), with ovarian
(n= 29, 25.7% of total ovarian), liver hepatocellular carcinoma
(n= 26, 10.4% of liver samples) and pancreatic cancers (n= 18,
7.5% of total pancreatic) overrepresented in this set.
To test for potential clinical relevance of this SCNR pattern, we
compared the overall survival of SCNR cases (n= 177), with high
SV heterogeneity cases (n= 650), and all remaining cases (n=
447) for which overall survival was recorded, stratified on age,
tumour histological subtype, and number of SVs. These groups
showed significantly different survival probabilities (p= 0.006,
likelihood-ratio test), with median survival times of 1236, 1470
and 2907 days, respectively (Fig. 6b). This resulted in a hazard
ratio of 1.930 for SCNR cases, significantly higher compared with
the baseline cohort (p= 0.0014, Z-test). In contrast, the high SV
heterogeneity cases had a hazard ratio of 1.302 (p= 0.084, Z-test).
Given the high number of ovarian samples within the SCNR
cohort, we also considered whether fold-back inversions (FBI)
were enriched, as they have been previously associated with poor
prognosis28. We found no evidence for enrichment of FBIs (see
Supplementary Fig. 6 and methods for further details), suggesting
that the SCNR genotype might arise from an independent
mechanism.
To test if these SCNR events were the result of a single complex
rearrangement event (such as chromothripsis), or were simply a
set of unrelated rearrangements, we looked for clustered events,
and where possible, attempted to walk the derivative chromosome
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Fig. 4 SV clustering performance for dual versus single-end models. Performance of SVclone run on three-cluster in silico mixtures using either both
breakends of an SV, or a single end. The first column shows the cluster number error (three-inferred cluster number), and the mean CCF error, where true
and inferred clusters are matched based on their order (see Methods). The second column shows the mean variant CCF and multiplicity error compared
with the ground truth CCF. The third column shows the subclonal classification sensitivity and specificity using sample membership of the variant (i.e. a
variant is classified as clonal if present in both samples of the mixture, and subclonal otherwise).
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(i.e. Korbel’s29 fourth statistical criterion for chromothripsis,
indicating that the fragments of a given chromosome form a
‘walkable’ chain of segments through consistent orientation).
SCNR events were ~26% more likely to be part of a complex
event, compared with background (39% vs. 31% in absolute
terms; p= 0.002, two-sided t test on proportion of linked SVs
between SCNR and other samples). Overall, 50% of these
clustered SCNR events were linked by at least one inter-
chromosomal translocation, compared with only 22% of other
samples (see Supplementary Table 2), suggesting these events can
span multiple chromosomes. We found a slight increase between
the fraction of chromosomes that could be walked between SCNR
(2.7%) and other samples (2.1%), however this was not significant
(p= 0.4029, two-sided t test). Overall, these data suggest that
subclonal events present in SCNR samples are likely enriched in
complex, interrelated rearrangements.
To provide some insights into the aetiology of the SCNR
genotype, we looked for an enrichment of SNVs/INDELs in
known cancer drivers, which may cause the SCNR genotype.
Specifically, we considered clonal (CCF > 0.7) mutations as
they may reveal predisposing drivers to an SCNR genotype. We
found an enrichment of TP53 mutations (40.11% of SCNR
samples) compared with background (14.54% of other samples;
FDR < 0.0001, hypergeometric test). The enrichment of TP53
is consistent with the reported link between TP53 mutations
and complex rearrangements30. However, an enrichment
of TP53 SNVs/INDELs was also observed in the high SV
heterogeneity cohort (36.77% of high SV heterogeneity
samples), along with KRAS and CTNNB1 (all FDR < 0.001),
suggesting that TP53 may be necessary but not sufficient for an
SCNR genotype.
Finally, to determine whether the enrichment of subclonal
neutral SVs within SCNR samples harboured functional con-
sequences, we identified all driver genes with candidate bi-allelic
hits involving an SCNR. We considered a candidate bi-allelic hit
as two separate mutation events affecting the same gene (copy-
number loss, an SV within the gene body and/or an SNV/
INDEL). We found that 62.15% of SCNR samples had at least one
subclonal balanced rearrangement affecting a driver gene that was
also affected by another mutation, almost double the rate found
in the high SV heterogeneity cohort (32.15%) (Supplementary
Table 3). This indicated that functionally-relevant consequences
of the SCNR genotype are likely.
Discussion
Here we have presented an integrated method for inferring the
cancer cell fraction of structural variation breakpoints, and have
demonstrated the importance of considering the clonality of
neutral rearrangements. In cancers where copy-number neutral
rearrangements are common, a significant portion of the clonal
landscape has remained, until now, unexplored.
Despite the successful applications of SVclone demonstrated
here, it is important to consider some of its limitations. In this
work, our clustering model considers all SVs as independent
events despite the fact that in some cases these SVs may be part
of the same complex rearrangement. Complex rearrangements
are not identified by SVclone’s classification framework, how-
ever, users may specify their own types, if known. As more
sophisticated methods for classifying complex SV events
become available, this could be integrated into the algorithm
framework. Another limitation to consider is that all CCF
clustering-based methods are affected by the power to detect
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Fig. 5 SV clustering performance incorporating background subclonal copy-number states. Performance of SVclone run across the three-cluster in silico
mixtures using either clonal background copy-number states, or clonal plus subclonal states. The first column shows the cluster number error (three-
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shows the mean variant CCF and multiplicity error compared with the ground truth CCF. The third column shows the subclonal classification sensitivity and
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variants and accurately estimate their VAFs. We present an
extensive analysis investigating the effects of tumour purity,
coverage and copy number (for SNVs) on the power to detect
clones and subclonal mutations in Dentro et al.25, which is also
applicable to SVs.
Inferring the evolutionary history of SVs from whole-genome
sequence data is a challenging problem. One of the key goals in
the field is to derive a clone tree that depicts the acquisition of
SVs over time and their relationship to clonal expansions during
tumour evolution. To achieve this, a number of key variables
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must be inferred from the data: variant allele frequencies of SV
breakpoints; number of DNA copies harbouring SV breakpoints
(also known as multiplicity), the cancer cell fraction of SVs,
cancer cell fraction of clones, and a clone phylogeny. No one
method exists that can simultaneously infer all variables, but
rather existing methods tackle subsets: Fan et al.: VAF31, WEA-
VER: VAF + clonal multiplicity32, TUSV: subclonal multiplicity
+ clone CCF + phylogeny + (additionally) clone copy number33,
Meltos: VAF + phylogeny34, and SVclone: VAF + subclonal
multiplicity + approximate clone CCF + SV CCF. At present
these methods need to be combined to achieve a more complete
picture of the evolution of SVs (e.g. WEAVER + TUSV33 or
SVclone + Meltos34). Thus, there remains an opportunity for
future development of an algorithm that can simultaneously infer
all variables.
Inferring the evolution of all variant classes, including SVs, SNVs,
SCNAs, indels, and their respective clonality will ultimately be
required to gain a more complete picture of the tumour hetero-
geneity landscape. We have presented an integrated software
package for modelling the cancer cell fraction of structural variation
breakpoints using single sample whole-genome sequencing data
and have demonstrated its application by identifying patterns of
subclonal variation. This software enables further exploration and
quantification of tumour heterogeneity, and moves us closer to an
integrated approach to modelling tumour heterogeneity.
Methods
Data input. The SVclone algorithm requires, at a minimum, a list of SV break-
points and associated tumour BAM file. SV breakpoints can be provided as a VCF
or as a tab-delimited file of paired single-nucleotide resolution break-ends. Using
an SV caller with directionality of each break-end is recommended. The Socrates24
output format is natively supported and allows additional filtering by repeat type
and average MAPQ. An associated paired-end, indexed whole-genome sequencing
BAM file is required. In the filter step, copy-number information can be added in
Battenberg15, ASCAT35 or PCAWG consensus copy-number formats to aid in
correcting VAFs. SNV input is also supported in multiple VCF formats (sanger,
mutect, mutect call-stats and PCAWG consensus). Further details of input formats
can be found in the repository README file.
SV annotation. To accurately calculate variant allele frequency (VAF) of structural
variants, the following information is required: (i) the single-nucleotide location of
loci comprising each breakpoint; (ii) the direction in which the break faces, i.e.
whether the breakpoint is on the left (−) or the right side (+) of a locus that
connects to the distant locus; and (iii) the classification of the SV. SV directionality
affects read counting, as only reads on one side of each break-end will correspond
to a specific breakpoint.
SVclone incorporates basic methodology to infer the breakpoint direction (ii)
and classification (iii) of the SV, however, we recommend using the information
provided by the SV caller if it is available. SVclone will infer the directionality of
each break-end by determining which side of the break-end has soft-clipped reads.
If SVclone finds evidence of soft-clips lying on both sides of the break-end (i.e. at
least 10% of soft-clipped reads support the opposite directionality), we consider the
directionality for this break-end as mixed (i.e. multiple break-end pairs are
involved for this event). If only one break-end of a pair has mixed directionality,
the SV will be split into two events, one where the mixed-evidence locus is (−), and
the other end is (+). If both ends have mixed directionality, we attempt to resolve
this by searching the SV input for other SV events matching the SV break-ends,
considering the following scenarios (see Supplementary Table 4 for a summary).
We denote each SV as j= 1..J; i∈ [l, u] where l= lower break-end locus and u=
upper break-end locus, l < u if the chromosome is the same, or the lower of the
chromosomes for inter-chromosomal translocations.
SV directionality inference. Directionality is determined for each SV as follows:
(i) neither l nor u matches any other event: the SV breakpoint is considered to be
(−, −), and a new SV breakpoint is created with directionality (+, +); (ii) both l
and u match (within a threshold): we consider one pair’s directionality as (−, −)
and the other pair’s as (+, +); (iii) two matching breakpoints are found, each
break-end matching one locus of each partner only: if the positional rankings of the
three SV breakpoints (on a single chromosome) are [(1, 2), (2, 3), (1, 3)], we
consider this a translocation event, and assign the directions of [(+, −), (+, −),
(−, +)]; (iv) more than two matching breakpoints are found: the SV breakpoint is
considered a complex event, and is discarded at the count step.
The directionality inference does not utilise local realignment of reads. The
functionality is not intended to provide comprehensive and robust annotation. We
recommend that directionality be inferred from the SV caller of choice.
SV classification. After resolving directionality, we employ a decision-tree based
approach to classify SV events into categories if this information is unavailable
from the SV caller (see Supplementary Fig. 7). We consider six simplified categories
of rearrangements: inversions, deletions, tandem duplications, interspersed dupli-
cations and intra- and inter-chromosomal translocations. Inversions refer to a
flipping of a segment of DNA, where the head of one segment joins the tail of
another at both ends. Deletions are considered a loss of DNA at a locus where the
flanking non-deleted segments join directly, without the intervening deleted
sequence. Duplications are split into two categories: tandem and interspersed. The
former category consists of a duplication joining tail to head immediately one after
another. In the latter case, the duplication may be interspersed anywhere within the
same chromosome. An intra-chromosomal translocation is similar to interspersed
duplications, except that the original mobile element is deleted rather than
retained. Inter-chromosomal translocations are defined as any joining event
involving different chromosomes.
The classification heuristics are shown in Supplementary Fig. 8 and are
summarised as: (i) inversion (INV): (l, u) directionality matches, i.e. (+, +) or
(−, −), and there are 1 or 2 breakpoints corresponding to the inversion event; (ii)
deletion (DEL): (l, u) directionality is (+, −), where l < u; (iii) tandem duplication
(DUP) - breakpoint directionality is (−, +), where l < u; (iv) interspersed
duplication (INTDUP): requires two breakpoints, (l, u)1 and (l, u)2 where l1 ≈ l2
(within 100 bp) and u1 ≠ u2 (one breakpoint has a tandem duplication signature
and the other a deletion signature, i.e. (l, u)1= (−, +) and (l, u)2= (+, −)); (v)
intra-chromosomal translocation (TRX): the same as an interspersed duplications,
except with the presence of a third breakpoint (l, u)3, classified as a deletion that
spans the mobile element: l3 ≈ u2, u3 ≈ u1 and (l, u)3= (+, −). To successfully
classify a translocation, the deletion ends must be within 6 bp (by default) of both
ends of the mobile element; and (vi) inter-chromosomal translocation (INTRX) -
the only criteria is that the chromosomes of l and u do no match, no directionality
is considered.
Read counting. We consider three types of reads that cross the respective break-
ends (l, u) (within 6 bp):
si= sl+ su: supporting split reads at l and u respectively. These are variant reads
(supporting the break) where one of the read-pairs lies across the break-end by a
specified number of base-pairs, which must be greater than the soft-clip threshold
(10 by default for 100 bp reads).
cj: supporting discordant (spanning) reads, i.e. reads that span across the (l, u)
breakpoint, where each read of the pair lies on one side of the break, effectively
spanning the breakpoint (see Supplementary Fig. 9). The insert distance is
calculated by both reads’ distance from their respective breakpoint at both ends.
One of the reads may also be soft-clipped at the breakpoint, and still be counted as
a supporting discordant read (these reads are counted under the spanning read
category). In addition, the read orientation of both reads is also checked to ensure
both reads are oriented towards the break (this is always the case for a true
spanning read supporting the breakpoint).
(ol, ou): normal read counts at l and u respectively. Either the read or the insert
between the reads must lie across the breakpoint locus. These are reads derived
from alleles not supporting the breakpoint. The outside ends of each read pair must
overlap the breakpoint boundary by at least the specified base-pairs (10 by default
for 100 bp reads) to be counted. Reads must not be soft-clipped above a small
threshold (6 bp by default).
Fig. 6 Application of SVclone to PCAWG cohort. a A 2D density plot of the fraction of subclonal SVs versus SNVs for PCAWG samples (n= 1169) (a
variant under 0.7 CCF was considered subclonal). b Survival curves representing patients divided into those with a SCNR pattern, those with high subclonal
SV fraction, or neither. c A circos plots for an example SCNR pattern tumour (Liver Hepatocellular carcinoma, tumour WGS aliquot 2bff30d5-be79-4686-
8164-7a7d9619d3c0). The outside track represents the copy number across the genome and the inner lines indicate SVs. Blue lines represent clonal SVs
and red lines represent subclonal SVs. d A CCF histogram of sample 2bff30d5-be79-4686-8164-7a7d9619d3c0’s SNVs. e A CCF histogram of 2bff30d5-
be79-4686-8164-7a7d9619d3c0’s subclonal SV’s colour coded by SV category. f A CCF histogram of 2bff30d5-be79-4686-8164-7a7d9619d3c0’s
clonal SVs.
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Supporting read calculation. Supporting reads are only counted if reads match
the specified break-end directionality; this avoids double-counting of reads for
events where reads are present at both sides of the breakpoint, such as inversions
and translocations (these events consist of ≥2 breakpoints per event). All reads that
are counted towards the supporting or normal read totals must have an insert size
(fragment size) < μins+ (3·σins), where μins= the mean of the insert size and σins=
the standard deviation of the insert size. (The insert size for supporting spanning
reads is considered the adjusted insert size for this criterion.) This is a quality-
checking measure to ensure only high-confidence reads are counted. We consider
both spanning and split reads together as the total supporting read count: bi,j=
si,j+ ci,j.
SV breakpoints where at any break-end the average read depth exceeds λ·maxnj
are considered high depth regions and are ignored, where λ is the expected number
of reads per locus and maxnj is the maximum expected copy-number value
(coverage and maximum expected copy number can be defined by the user). These
breakpoints are likely caused by repetitive regions, rather than true copy-number
amplifications, and are not suitable for inference of clonal composition. Bed
filtering has been incorporated to automatically ignore breaks falling within
specified regions (to accommodate blacklists such as DAC—www.encodeproject.
org/annotations/ENCSR636HFF/).
In order to determine whether micro-homology was likely to play a large role in
the read counting process, we analysed the distribution of breaks containing micro-
homologies across the PCAWG samples used in the paper analysis (using
PCAWG’s consensus SVs v1.6). We found that the mean and median micro-
homology lengths were 1 and 2.4 respectively. Micro-homologies ≤ 6 bp in length
are handled by the variable threshold used by the read counting step. We found
that 6.17% of SVs had micro-homologies greater than 6 bp and <1% of SVs had
micro-homologies greater than 20 bp. Given the minority of SVs affected, handling
of longer micro-homologies is outside the scope of this work, and such SVs should
be filtered out.
Non-supporting read calculation. For each SV, normal reads are counted at the
break-ends resulting in two normal read count totals (ol, ou). In the case where the
SV results in a gain of DNA (interspersed and tandem duplications), the normal
read count must be adjusted. We consider the SV classification κj for an SV j, where
κj∈ {DEL, DUP, INTDUP, INV, TRX, INTRX}(respectively: deletions, duplica-
tions, interspersed duplications, inversions, translocations and inter-chromosomal
translocations). We define two subsets κgain= {DUP, INTDUP} where normal
reads at the variant population's break-ends are unaffected at the variant allele, and
κnon-gain= {DEL, INV, TRX} where the normal reads at the variant population’s
breakends are replaced by supporting reads. We compute an adjustment factor,
AFnorm ¼ 1 
t
np
 !
; ð1Þ
where t is the tumour content and np the tumour ploidy. The normal read counts of
all DNA-gain events are then multiplied by this adjustment factor (oi,j= oi,j·AFnorm
if κj∈ κgain), while events that are not DNA-gains remain unadjusted.
Anomalous reads. Reads that cross the SV boundary but do not meet the
requirements for split, spanning or normal reads are considered anomalous and do
not contribute to read counts. Reads can be considered anomalous for numerous
reasons: (i) the insert distance is greater than μins+ (3·σins), (ii) discordant reads do
not face the break, (iii) the read is soft-clipped at both ends, (iv) the read is soft-
clipped but is either not in the vicinity of the breakpoint, boundary or the soft-clip
is below the threshold, or (v) the reads support the break in the opposite direction,
but have not been called by the SV calling algorithm. To investigate points i-iv, we
investigated anomalous reads in the 100% purity deletion simulations, and flagged
an average of 8.74 anomalous reads per breakpoint per 246.18 considered (3.57%)
from the extracted regions around both break-ends of a breakpoint (these reads are
proximal to the breakpoint and may not directly cross it). Upon manual inspection,
we found that anomalous reads largely fell in the (iv) category, i.e. insufficiently
long soft-clips or the reads genuinely did not cross the breakpoint boundary.
Manual analysis uncovered no consistent under-counting of supporting reads.
Filtering variants. While tumours may contain several thousand unique muta-
tions, typically SVs number in the dozens to low-hundreds (for instance, in breast
cancers36). With typically 10-fold fewer variants, each variant utilised in clustering
has a higher influence on the clustering results. A conservative approach to filtering
is therefore required to minimise noise propagated through variants with spurious
read counts. The following filtering criteria have been implemented, with default
values, to provide a baseline for minimising noise. These variants may be adjusted
in cases by the user to tailor their noise thresholds to the samples under con-
sideration. We filter on the following criteria:
Germline variants. The output from the count step for the corresponding patient’s
germline sample can be supplied to filter out any events where there is at least one
supporting read in the germline for breakpoints that are considered the same event
(both break-ends match directionality and are within 6 bp of each other).
SV size. If a breakpoint is on the same chromosome, SV size (u− l) must be larger
than the fragment size (by default) as otherwise supporting and normal reads may
be difficult to distinguish. This criterion is only considered for intra-chromosomal
events.
Minimum support. The SV breakpoint must have at least one split and one
spanning read supporting the break (si,j ≥ 1, ci,j≥ 1). Custom minimum values can
be specified.
Minimum depth. The minimum supporting+ normal reads must be greater than
the minimum depth for each break-end: (bi,j+ ol) > bmin and (bi,j+ ou) > bmin.
(Default bmin= 2).
Copy-number state. If copy-number input is provided, either l or u must have a
valid copy-number state for each variant. The major+minor copy numbers must
be at least 1 for a state to be considered valid.
Optionally, in some instances it may be appropriate to filter on several further
criteria:
Copy-number neutral regions. Filters out variants with copy-number states that
are not 1, 1 for major, minor alleles. Used if copy-number calls are unreliable and
sufficient regions of neutral copy-number exist.
Subclonal copy-number regions. This filter may be invoked to remove any var-
iants with subclonal copy-number states. This reduces the copy-number search
space, which is useful for clustering high numbers of variants.
Assigning background copy-number states. Allele-specific copy-number varia-
tion can be supplied as input to SVclone in order to attach copy-number states to
break-ends. We assign the estimated copy-number state that occurred before the
SV occurred. For intra-chromosomal SVs, this involves obtaining the copy-number
state upstream of the lower break-end and downstream of the upper break-end. For
inter-chromosomal translocations, we obtain the copy number in the opposite
direction of the break-end directionality. See Supplementary Fig. 10 for a con-
ceptual schematic and Supplementary Table 5 for the mathematical representation.
Battenberg15 output format is preferential to capture subclonal CNAs, however,
ASCAT35 is also supported. If no CNA information is supplied, the algorithm
assumes that the total tumour copy number ðntott Þ matches the normal copy
number ðntotn Þ, with no subclonality. For robustness of the algorithm results, it is
recommended that copy-number information be supplied if available. If Battenberg
input is defined, the first solution set of segmentations in the input is considered.
We define the total copy number as the sum of each clone’s copy number, weighted
by the clonal fraction:
ntott ;i;j ¼
X2
r¼1
ρr;i;jntott ;r;i;j; ð2Þ
where ntott ;r;i;j and ρr;i;j are the total copy number and copy-number fraction per
(copy number) clone r 2 1; 2.
Clustering. The clustering step of SVclone simultaneously computes SV CCFs and
clusters SVs of similar CCF, based on purity, ploidy and copy-number status of the
normal, reference and tumour populations. SVclone uses a bespoke clustering
algorithm that takes read counts and copy-number states at both break-ends of the
same SV as input, and utilises a Bayesian mixture model, implemented using
variational inference, to approximate posterior distributions for unknown para-
meters. The algorithm determines the number of clusters automatically and infers
average CCF per cluster, as well as the multiplicity of each variant (the number of
mutated chromosomal copy). The model extends our previous method, Ccube26,
for estimating and cluster CCFs for SNVs by allowing it to deal with additional
read and copy-number profiles from the two break-ends. This is achieved by
assigning the two break-ends of an SV to the same CCF cluster. Below is a detailed
description of our clustering method.
Read distribution. Let i 2 1; 2 and j 2 1; 2; :::; J be the indexes of break-ends and
breakpoints respectively. We assume the supporting read counts from both
breakpoints are independently distributed following two different Binomial dis-
tributions. The joint probability mass function of the supporting read counts is the
following:
p bjjdj; f j
 
¼ Q2
i¼1
Binomial bi;jjdi;j; fi;j
 
; ð3Þ
where bi,j, di,j, and fi,j denote the number of supporting reads, the number of normal
reads, and the probability of observing one support read. The bold font variable
are collections of these across both breakpoints, bj ¼ ½b1;j; b2;j, dj ¼ ½d1;j; d2;j, and
fj ¼ ½f1;j; f2;j.
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We model the probability of sampling a variant read given variant locus j at
break-end i as coming from a binomial distribution with trials d (read depth bj+ o)
and probability fi,j,k:
bi;jjdi;j; fi;j;k  Binomial bi;jjdi;j; fi;j;k
 
; ð4Þ
where bi,j= si,j+ ci,j, (si,j is the number of split reads and ci,j the number of
spanning reads supporting the break). We assume the two breakpoints are
conditionally independent of each other given the same CCF. In order to calculate
fi,j,k we require the tumour purity estimate t and copy-number information:
fi;j;k ¼ wi;jϕk þ ϵ;with wi;j ¼
t mi;j 1 ϵð Þ ntott i;jϵð Þ
1 tð Þntotn i;j þ tntott i;j
; ð5Þ
where ntotni;j and ntott i;j are the total copy number of the normal and tumour
population respectively and ε is the sequencing error constant. ϕk; k 2 1; :::;K
represents the unknown CCF, and is indexed by k, representing the kth cluster. The
other unknown parameter is mi,j, the number of mutated chromosomal copies, also
known as the multiplicity of the variant. See below for how these are inferred.
To test the appropriateness of the binomial distribution for SV allele
frequencies, we studied the distribution of clonal SV VAFs from the two samples
used in the in silico mixtures (see below for more details). A likelihood-ratio test
was performed to compare the goodness of fit of each SV using a binomial and a
beta-binomial distribution. We found that the binomial distribution adequately fit
most (89%) SVs. In addition, our variational formulation mitigates potential
overdispersion by producing a similar effect to a beta-binomial model. The
assignment probability is computed as an expectation of the binomial distribution
with respect to the posterior CCF distribution; therefore, the uncertainty within the
probability of success is integrated out when making assignments. Uncertainty is
normally distributed in our model, while being beta-distributed in a beta-binomial
model—the benefit of our choice is a fully tractable variational approximation in
which all its parameters can be efficiently estimated. In the beta-binomial case, the
key overdispersion parameter is difficult to estimate at typical depths obtained in
whole-genome sequencing (~50x). This difficulty is evident in the high variance
and lack of clear convergence observed in PyClone’s MCMC traces of its
overdispersion parameter (Supplementary Fig. 11).
Posterior inference. We estimate the unknown ϕk andmi,j in Eq. (5) by variational
inference (VI). Specifically, the algorithm obtains a posterior distribution over ϕk
and a point estimate of mi,j. For ϕk, we specify a Gaussian distribution as its prior.
The choice is motivated by its convenience in deriving a fully trackable VI method.
As a result, we obtain a maximum pseudo marginal likelihood estimator for mi,j.
The model employs a finite mixture model, hence, we introduce additional para-
meters such as the mixing coefficient πk and the cluster assignment variable zj,k,
which have the standard Dirichlet and Categorical prior respectively. We use this
formulation for both clonal and subclonal copy-number settings. In regions of
clonal copy number, the mapping is exact. In the presence of subclonal copy
number, the mapping is an approximation, in which ntott is replaced by the
weighted average total tumour copy number. Here we provide a detailed
description of the inference.
The variational inference method maximises the evidence lower bound (ELBO)
of the marginal likelihood of the model:
logpðBjM;HÞ ¼ log
Z
pðBjZ; ϕ;M;HÞpðZjπÞpðϕÞpðπÞdZdϕdπ
¼ log
Z
pðB;Z; ϕ; πjM;HÞdZdϕdπ
 Eq Z;ϕ;πð Þ logp B;Z;ϕ; πjM;Hð Þ½   Eq Z;ϕ;πð Þ logq Z;ϕ; πð Þ½ ;
ð6Þ
where B= {bi,j}, Z= {Zi,k}, ϕ= {ϕk}, π= {πk}, M= {mi,j}. We use H to represent all
fixed variables.
Assuming independence among the unknowns, qðZ; ϕ; πÞ ¼ qðZÞqðϕÞqðπÞ, the
ELBO is maximised by the following solution:
q Zð Þ / exp Eq ϕ;πð Þ logp B;Z; ϕ; πjM;Hð Þ½ 
 
qðϕÞ / exp EqðZ;πÞ logpðB;Z;ϕ; πjM;HÞ½ 
 
q πð Þ / exp Eq Z;ϕð Þ logp B;Z; ϕ; πjM;Hð Þ½ 
  ð7Þ
further details about these approximations can be found in26.
The multiplicities are estimated by the following maximisation formula:
bmi;j ¼ argmaxmi;j2Ξi;j PK
k¼1
Eq zi;k ;ϕkð Þ logp bi;jjdi;j; fi;j;k; zi;k ¼ 1
 h i
ð8Þ
The difference between clonal and subclonal copy number is reflected in the set
of possible multiplicities:
Ξi;j ¼
1; ¼ nmajt ;i;j
n o
; if tumour copy number at SV i; j is clonalP2
r¼1 ρr;i;jxi;j : xi;j 2 0; ¼ nmajt ;r;i;j
n o
; if tumour copy number at SV i; j is subclonal:
8><>:
ð9Þ
with Ξi;j ¼ f1; ¼ nmajt ;i;jg if the tumour copy-number segment at SVi,j is clonal,
and Ξi;j ¼
P2
r¼1 ρr;i;jmi;j : mi;j 2 0; :::nmajt ;r;i;j
n o
if the tumour copy-number
segment at SVi,j is subclonal. Where nmajt ;i;j is the tumour major copy number at
SVi,j. ρr;i;j and nmajt ;r;i;j are the fraction and major copy number of the tumour
subclonal r at SVi,j.
The variational inference algorithm is run over a range of possible cluster
numbers (by default 1..6) and multiple repeats (by default 5). The solution with the
best ELBO is selected.
Calculating variant CCFs. Given the estimated multiplicity, mi,j, we infer CCF at
individual variant level. In our Binomial model, the probability of observing a
variant supporting read is specified as fi;j;k ¼ wi;jϕk þ ϵ. We replace the cluster-
level CCF parameter ϕk with variant-level CCF parameter ϕi,j. As a result, we have
ϕi;j ¼
fi;jϵ
wi;j
. The removal of subscript k in fi,j reflects the change in CCF levels.
Under the Binomial distribution assumption for variant supporting read counts,
fi;j ¼ E½VAFi;j, VAFi;j is an unbiased estimator of fi,j. Therefore, ϕi,j can be esti-
mated as
VAFi;jϵ
wi;j
. Note that, the linear relationship doesn’t support a natural bound
on CCF. We cap the maximum of CCF at 2. Finally, we have
CCFi;j ¼ min 2; VAFi;jϵwi;j
 
ð10Þ
For SVs, the mean of these two CCFs is used as the representative CCF per SV.
Post-assignment of variants to clusters. In some cases, the number of filtered
SVs in a sample is too small ⪅ 10 to perform reliable clustering. To estimate the
CCF of these SVs, we leverage clustering results from SNV data. To demonstrate
this approach, we use the subscript post to denote variables of the post-assigned SVs,
e.g. Bpost. The strategy is to use q(ϕSNV) (the subscript SNV emphasises that the
distribution is constructed from SNVs) from Ccube results as a reference model,
then assign SVs to clusters in q(ϕSNV). Algorithmically, given that Ccube and
SVclone both assume q(ϕ) to be Gaussian, one can use the SNV-based q(ϕSNV) to
compute q(Zpost) and q(πpost) for the SVs.
Here, we set out to update q(πpost) in addition to the assignment variable q
(Zpost). The reason for this is to avoid the post-assignment mimicking the mixing
proportions in SNV results. The dimensions of q(Zpost) and q(πpost) are set to be
compatible with the number of clusters in q(ϕSNV). More precisely,
qðZpostÞ / exp Eq ϕSNV ;πpostð Þ logp Bpost;Zpost; ϕSNV; πpostjM;Hpost
 h i 
q πpost
 
/ exp Eq Zpost ;ϕSNVð Þ logp Bpost;Zpost; ϕSNV; πpostjMpost;Hpost
 h i  ð11Þ
The multiplicities of the post-assigned, bmi;j;post , are estimated as:
argmaxmi;j;post2Ξi;j
PK
k¼1
Eq zi;k;post ;ϕk;SNVð Þ logp bi;j;postjdi;j;post; fi;j;k; zi;k;post ¼ 1
 h i
ð12Þ
where the set of possible states Ξi;j is of the same form with the settings in the main
clustering algorithm, Eq. (9). Similar to above, and SVs that were initially filtered
can be post-assigned to the SNV or SV clusters.
Quality control. We use the same quality-checking steps for both clustering and
post-assign. They are made of three steps: (1) remove empty clusters, (2) remove
small clusters with less than 1% of the data assigned, (3) merge clusters with cluster
means less than 10% apart. In each step, the model parameters are refined with the
same variational inference procedures.
SV simulation. SVs were simulated by first rearranging the reference genome to
create an artificial genome containing SVs, and then simulating reads with Sim-
Seq37 from this rearranged reference. The reads were then mapped back to the
original, unmodified reference genome using bowtie2 with the local alignment
flag38. SV size was randomly chosen among the size categories 300–1 kb, 2–10 kb
and 20–100 kb with equal probability for each category.
We simulated a single, heterozygous chromosome 12 (being roughly
representative of genome-wide GC-content) with SVs of a single type at every
100 kb interval. Samples containing only deletions, translocations, inversions and
duplications were generated at the tumour purity levels of 100, 80, 60, 40 and 20%.
We generated 100 bp paired-end reads with an average fragment size of 300 bp and
an insert-size standard deviation of 20 bp. The SV events were assumed to always
occur in the heterozygous fashion, hence the ‘true’ VAF was always considered to
be half of the simulated purity value. To achieve the effect of differing purities,
simulated normal reads were mixed with tumour samples with coverage equivalent
to λt2 and normal read coverage of
λð1tÞ
2 where λ represents the expected total read
count at a locus. We ran simulations at 50x coverage, typical for WGS data by
simulating 50L300 total reads per simulation where L is the chromosome length (post
rearrangement) and 300 is the fragment length. The number of reads generated for
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genomes with variants that changed the total size of the genome (deletions and
duplications) was adjusted by the new genome length.
The list of SV breakpoints for each simulation run was collated, directions were
inferred and each breakpoint was classified using SVclone’s annotate step. Any
breakpoints where the direction could not be inferred correctly, or their
classification was incorrect were discarded. The resulting set was run through
SVclone’s count step with default parameters. SVs were then filtered through the
filter step, and adjusted VAF field was used to compare variant frequencies at
corresponding purity levels.
Prostate sample mixing. The metastatic samples bM (A) and gM (B) from Patient
00123 were chosen due to their similar coverage (51.5x and 58.9x) and purity (49
and 46%). Previous analysis by Hong et al.23 showed that these metastases shared a
common ancestral clone, had no evidence of subclonality, and contained a number
of private SVs and SNVs. Mixing two clonal metastases from the same patient has
many advantages over spike-in approaches including: realistic sequencing noise,
realistic subclonal mixing of SVs, SCNAs and SNVs, and a natural branching clonal
architecture with both clonal and subclonal mutations present. We generated a
total of nine samples with subclonal mixes of reads sampled at percentages 10–90,
20–80, 30–70, 40–60, 50–50, 60–40, 70–30, 80–20, and 90–10 for metastasis A and
B, respectively. Three clusters are expected to be revealed upon mixing: shared
variants present at 100% CCF, one cluster at bM’s mixture frequency and one
cluster at gM’s mixture frequency. We also generated mixtures of four and five
clusters each. The four cluster mixture was constructed by subsampling bMʼs odd
and even chromosomes separately at 20 and 60% respectively, and then mixing this
with a 40% subsampled mixture from gMʼs odd chromosomes only (effectively
creating a mixture where odd and even chromosomes comprise 60% of either one
or both samples, with CCFs of 20%, 40 and 60%). Similarly, the five-cluster mixture
was constructed by subsampling bMʼs odd and even chromosomes separately at 80
and 60% respectively, and gMʼs odd and even chromosomes at 20 and 40%
respectively (effectively creating a mixture where odd and even chromosomes
comprise 100% of both samples, with CCFs of 20, 40 and 60 and 80%).
A merged variant list was created for SVs and SNVs, containing both the
individual sample’s high-confidence calls. SV breakpoints were then run through
SVclone’s complete pipeline, and SNVs were counted at each variant locus using
Samtool’s mpileup39 and pileup2base (https://github.com/riverlee/pileup2base) for
each mixture. Battenberg was run on each mixture to obtain SCNA data and purity
estimates (which were used as the purity values for both SVclone and PyClone). A
truth set was created for benchmarking purposes, constructed for SV, SNV and
SCNA by determining whether the variant was unique to one sample, or shared
in both.
In silico mixtures were created using the subsample and merge functions from
SAMtools v1.2. copy numbers were obtained from Battenberg on each merged
sample with default parameters. To construct the breakpoint list for input into
SVclone’s annotate step, Socrates was run on the individual bM and gM samples,
then run through SVclone’s annotate and count steps (using Socrates’ directions,
filtered on simple and satellite repeats using the repeat-masker track (repeatmasker.
org) and a minimum average MAPQ of 20). The resulting bM and gM SVs were
then merged and filtered against the germline. copy numbers were matched using
corresponding Battenberg subclonal copy-number output. The merged SV list was
used as the set of SV calls for the annotate step for each mix.
The reference and variant alleles were counted at each of the 9810 SNVs across
the different mixture proportion BAM files (Mutect variant calls from Hong et al.
were used with alleles recounted using Samtool’s mpileup and pileup2base (https://
github.com/riverlee/pileup2base) using a minimum quality and MAPQ cutoffs of
20 to count a base. Battenberg was run on each mixture and was used to provide
copy-number information for each variant locus, as well as the purity estimate for
both SVclone and PyClone. For SNV clustering, we filtered out any variants in
regions of subclonal copy number (PyClone does not support subclonal copy-
number handling). To improve performance, cluster labels from the PyClone traces
were obtained using the mpear function from the mcclust R package https://cran.r-
project.org/web/packages/mcclust. Variant and cluster CCFs were calculated from
the mean MCMC trace values. We subsampled 5000 variants from the resulting
SNV output per mixture and ran these variants through the PyClone algorithm for
2500 iterations with a burn-in of 1000.
Set ownership of SVs (whether the SV is present in bM only, gM only or shared
between the two), was determined by running the union list of variants through
SVclone against each 001 sample. If there were any supporting reads for both
samples, the SV was considered shared, otherwise it was considered unique to the
sample that it exclusively appeared in. For the SNVs, a variant was considered
exclusive to a sample if it was called in one individual sample’s consensus SNV list
only, and shared if it appeared in both lists. To test set ownership of SCNAs,
Battenberg calls run on bM and gM were analysed. Any SCNAs present in both bM
and gM (where start and end coordinates had to be at least within 5 kb of each
other) that contained the same allelic copy numbers were considered shared
SCNAs. Any SCNAs with partial matches (only one end matched, or copy numbers
differed) were discarded. All other SCNAs from were considered unique to their
respective samples. The mixture SCNAs were then compared with this list (where
both ends must match within a 5 kb boundary). The SCNA fraction that matched
the given sample’s allelic copy number was used as the SCNA’s CCF estimate. To
calculate mean cluster CCF error, we compared: (i) highest ground truth CCF to
highest derived cluster CCF, (ii) lowest ground truth CCF to lowest derived cluster
CCF, (iii) second-highest ground truth CCF etc. alternating between highest and
lowest in ranked order until either there are no more derived clusters or no more
truth clusters.
Determining optimal variant multiplicities and CCFs. To calculate the optimal
CCF per variant across all mixes, we took the true mixture state of the variant, and
inferred the best multiplicity. For example, in the 70–30 mixture, if an SV was
present only in bM and not in gM, the true cluster CCF of 0.7 was used as the ϕk
when calculating fi,j,k (the binomial probability of sampling a variant read for the
given locus). The multiplicity was then inferred using Eq. (6). An adjusted variant
CCF could then be determined using the same method outlined in the section titled
calculating variant CCFs.
Testing the distribution fit of SV allele frequencies. To test whether a binomial
model was appropriate for modelling SV VAFs, SVclone’s annotate to filter steps
were run on the bM and gM metastases from patient 001, retaining only variants
with copy-number neutral states (1/1 for major/minor allelic copy numbers). For
each variant, a binomial likelihood for the observed number of supporting reads
was calculated using pj= t/2 (the theoretical heterozygous variant frequency) and
dj equivalent to the observed variant’s adjusted read depth. A beta-binomial like-
lihood was also calculated where the β value was empirically estimated from the
data as:
β ¼ μ nð Þ μ2  μnþ σ2ð Þμ2  μnþ nσ2 ; ð13Þ
where μ ¼ μdðt=2Þ (mean adjusted depth multiplied by the theoretical hetero-
zygous variant frequency) and σ is the standard deviation of the observed sup-
porting reads. α was then estimated as:
α ¼  μβμdj ð14Þ
A likelihood-ratio test was then applied with one degree of freedom to each
variant with the binomial distribution as the null model, and the beta-binomial as
the alternative. Of 55 SVs tested in the bM sample, 6 SVs rejected the null model
(10.9%); 2 of 44 SVs (4.5%) rejected the null model in the gM sample. Therefore,
>89% SVs of moderate purity and coverage appeared to be consistent with the
binomial model, indicating that the binomial model is a reasonable choice of
distribution for SV data given the moderate coverage and purity of the analysed
datasets.
Copy-number perturbation experiments. We selected the 70–30 in silico mixture
due to its low mean variant CCF error for the SCNA perturbation experiments. In
order to perform experiments representative of the background copy-number
heterogeneity prevalence, we quantified the per-sample fraction of SVs that had
different background copy-number states across PCAWG. Supplementary Table 1
includes the medians of this measure cohort-wide and by histology group. We
observed a range of background copy-number heterogeneity across the cohort, with
a minimum (median) of 34% in non-Hodgkin lymphoma and a maximum
(median) of 74% in colorectal adenoma. The median across all cancer types was
0.53. Given this result, we investigated the same measure in the three-cluster in
silico mixtures and identified a lower background SCNA heterogeneity rate
(potentially due to SCNA averaging as background SCNA heterogeneity was higher
in the pure 001 bM and 001 gM samples) (see Supplementary Table 6). We
therefore randomly removed SVs with homogeneous background SCNAs until the
rate of heterogeneity was 50%, resulting in 45 SVs with homogeneous and het-
erogeneous background SCNA states, and used these data for downstream
experiments (see the SVclone_Rmarkdown notebook under code availability to
replicate this analysis).
SCNAs were perturbed as follows: (i) CN− 1: major alleles were subtracted by
one in the fraction A subclone in Battenberg. If the copy number was 1, subtracting
one from the minor allele was attempted. If the copy-number state was 1-0, no
modification was performed (only two SVs were unable to be changed); (ii) CN+
1: major alleles were incremented by one for the fraction A clone; (iii) Frac ± 0.3:
0.3 was added to the SCNA fraction for subclonal SVs, unless that modified
fraction were to exceed 0.9, in which case 0.3 was subtracted. The new SCNA
fraction of clone B was calculated as one minus the new fraction of clone A.
The above experiments perturbed the l side of each SV for the one-side
experiments, and both the l and u sides for both-side experiments. Performance
metrics were calculated as usual with the two single-end metrics averaged out
between the two runs (Supplementary Fig. 3).
Analysis of ICGC/TCGA pan-cancer samples. We utilised the pan-cancer ana-
lysis of whole genomes (PCAWG) October 12th 2016 consensus SNV call set, the
v1.6 consensus SVs and the consensus subclonal copy numbers (19th of January
2017). For a detailed explanation on how these were generated, see25. Annotate and
count were run using each sample’s associated mini-bam. Consensus purity and
ploidy estimates (January 9th 2017) were used. Sample SVs and SNVs were run
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separately through SVclone’s SV and SNV clustering model with default
parameters.
We considered only white-listed PCAWG samples that had sufficient power to
detect subclonality (number of reads per chromosome copy or NRPCC > 10; n=
1705, see Supplementary Note 1 for a list of samples). As a QC measure, we tested
the association of SV number with sample purity (Supplementary Fig. 12), and
found the variables to be uncorrelated (R2= 0.001). We also tested the rate at
which SVclone called single non-clonal clusters in PCAWG samples. Using a cutoff
of <0.7 cluster CCF, and considering only samples with >10 variants (of the
clustered variant type) the SV clustering reported one sample with single non-
clonal clusters across 1220 PCAWG samples with (0.0008%), and the SNV
clustering reported four samples across 1362 (0.0029%) samples. These results
indicated that rates of under-clustering were low, and were similar across the SV
and SNV clustering models.
We tested each PCAWG sample for the enrichment of balanced rearrangements
(inversions and inter-chromosomal translocations) below the CCF cutoff (0.7)
using a hypergeometric test, with the alternative hypothesis of P(X ≥ x), where
x ¼PJj¼1 ¼ 1½κj ¼ κbal and κj refers to a given SV’s classification. Survival
analysis was undertaken using the survival CRAN package (cran.r-project.org/
package= survival). Hazard ratios were calculated using the Cox proportional
hazards regression model, stratified by tier 4 tumour histology, age and the number
of SVs in 1–100, 101–200 etc. bins. We used a hypergeometric test to determine
whether any ICGC/TCGA contributors were overrepresented for SCNR samples
within each histology type and found no evidence of any significant over-
representation (using an FDR < 0.05 significance threshold). To determine whether
SCNR samples were overrepresented for fold-back inversions (FBI) in the ovarian
samples, we used a one-sided t test to compare SCNR samples to the high SV
heterogeneity and other subsets, and found no significance (p= 0.8056 and p=
0.4671, respectively). Supplementary Fig. 6 shows a boxplot of amplified FBI
fraction across the three subsets. For the clustering of breakpoints criteria, SVs were
tested on a per-chromosome basis (inter-chromosomal SVs were removed). The
ability to walk each derivative chromosome was tested using criteria for
chromothripsis tests A and F29. Chromosomes were only tested if they contained at
least four clonal and four subclonal rearrangements per chromosome.
A list of consensus coding driver genes was obtained from the curated PCAWG
coding driver genes (29th of September 2016). Patient-centric coding point
mutations were obtained from Sabarinathan et al. Table S2 40. CCFs were matched
using SVclone’s clustering results, and variants with a CCF < 0.7 were considered
subclonal. Enrichment of driver genes was computed using a hypergeometric test
for the SCNR and high SV heterogeneity cohorts using the driver mutations from
all 1705 samples as the complete sample set. Copy numbers were obtained from the
PCAWG annotated consensus clonal copy numbers (19th of January 2017). Loss of
heterozygosity was defined as any region where the minor allele was zero (X and Y
chromosomes in males were only considered in cases of complete loss). Copy-
number gains or amplifications were not considered. SV driver hits were defined as
any SV that affected at least one exon of a driver gene, and was not completely
outside the gene (i.e. at least one SV break-end must fall within the gene body. Any
regions with deletions (called as structural variants) that were also affected by copy-
number loss (called from copy number) were considered as one variant only to
avoid redundancy.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
In silico sample mixtures were generated from patient data derived from patient 001
from the Hong et al. study23. The data are available in the EGA Sequence Read Archive
under accession EGAS00001000942.
Somatic and germline variant calls, mutational signatures, subclonal reconstructions,
transcript abundance, splice calls and other core data generated by the ICGC/TCGA Pan-
cancer Analysis of Whole Genomes Consortium is described in ref 20 and available for
download at https://dcc.icgc.org/releases/PCAWG. Additional information on accessing
the data, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. In
accordance with the data access policies of the ICGC and TCGA projects, most
molecular, clinical and specimen data are in an open tier which does not require access
approval. To access potentially identification information, such as germline alleles and
underlying sequencing data, researchers will need to apply to the TCGA Data Access
Committee (DAC) via dbGaP (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login)
for access to the TCGA portion of the dataset, and to the ICGC Data Access Compliance
Office (DACO; http://icgc.org/daco) for the ICGC portion. In addition, to access somatic
single-nucleotide variants derived from TCGA donors, researchers will also need to
obtain dbGaP authorisation. Derived datasets described specifically in this manuscript
can be found at these locations:
https://www.synapse.org/#!Synapse:syn7596712 (consensus SVs)
https://www.synapse.org/#!Synapse:syn7357330 (consensus SNVs and INDELs)
https://www.synapse.org/#!Synapse:syn8042880 (consensus copy-numbers)
All the other data supporting the findings of this study are available within the article
and its supplementary information files and from the corresponding author upon
reasonable request. A reporting summary for this article is available as a Supplementary
Information file.
Code availability
The SVclone software, user documentation, and example data can be downloaded from
https://github.com/mcmero/SVclone. Ccube clustering code can be found under https://
github.com/keyuan/ccube. Code for generating all figures in the manuscript and the in silico
mixture samples can be found under https://github.com/mcmero/SVclone_Rmarkdown.
Code for simulating SVs can be found under https://github.com/mcmero/sv_simu_pipe.
The core computational pipelines used by the PCAWG Consortium for alignment,
quality control and variant calling are available to the public at https://dockstore.org/
search?search=pcawg under the GNU General Public License v3.0, which allows for
reuse and distribution.
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